G
Giampaolo Bianchini
Researcher at Vita-Salute San Raffaele University
Publications - 111
Citations - 5468
Giampaolo Bianchini is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 71 publications receiving 3610 citations. Previous affiliations of Giampaolo Bianchini include University of Milan & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
TL;DR: The most relevant molecular findings in TNBC from the past decade are discussed and the most promising therapeutic opportunities derived from these data are discussed.
Journal ArticleDOI
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
TL;DR: In this article, the authors describe the current and upcoming therapeutic landscape of triple negative breast cancer (TNBC) and discuss how an integrated view of the TNBC ecosystem can define different levels of risk and provide improved opportunities for tailoring treatment.
Journal ArticleDOI
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini,Luca Gianni +1 more
TL;DR: Findings indicate that immune-related markers can provide useful predictive information and that increased clinical activity might follow activation of the immune system, which defines a scenario in which the combination of immune modulation with trastuzumab, or other HER2-directed drugs, will result in augmented response and clinical outcome.
Journal ArticleDOI
Immunological differences between primary and metastatic breast cancer.
Borbála Székely,Veerle Bossuyt,Xiaotong Li,Vikram B. Wali,G Patwardhan,Courtney Frederick,Andrea Silber,Tristen S. Park,Malini Harigopal,Vasiliki Pelekanou,Meiling Zhang,Qin Yan,David L. Rimm,Giampaolo Bianchini,Christos Hatzis,Lajos Pusztai +15 more
TL;DR: Metastatic breast cancers are immunologically more inert than the corresponding primary tumors but some immune-oncology targets and macrophage and angiogenesis signatures show preserved expression and suggest therapeutic combinations for clinical testing.
Journal ArticleDOI
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
Takayuki Iwamoto,Giampaolo Bianchini,Daniel J. Booser,Yuan Qi,Charles Coutant,Christine Y. Shiang,Libero Santarpia,Junji Matsuoka,Gabriel N. Hortobagyi,William Fraser Symmans,Frankie A. Holmes,Joyce O'Shaughnessy,Beth A. Hellerstedt,John Pippen,Fabrice Andre,Richard Simon,Lajos Pusztai +16 more
TL;DR: Different biological processes were associated with prognosis and chemotherapy response in ER-positive and ER-negative breast cancers.